Fine‐tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic‐phase chronic myeloid leukemia: The choice of the right TKI for the right patient

In an era when tyrosine kinase inhibitors are gaining acceptance in the treatment scene of chronic‐phase chronic myeloid leukemia, this editorial focuses on the search for the optimal patient‐based frontline treatment option while evaluating a recent study by Tiribelli and colleagues, which is publi...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2023-09, Vol.129 (17), p.2610-2612
Main Authors: Nuhoğlu Kantarcı, Eda, Tolgay, Ece, Eşkazan, Ahmet Emre
Format: Article
Language:English
Subjects:
Chronic myeloid leukemia
Enzyme inhibitors
Humans
Kinases
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myeloid, Chronic-Phase - drug therapy
Molecular Targeted Therapy
Myeloid leukemia
Protein Kinase Inhibitors - adverse effects
Tyrosine
Tyrosine Kinase Inhibitors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In an era when tyrosine kinase inhibitors are gaining acceptance in the treatment scene of chronic‐phase chronic myeloid leukemia, this editorial focuses on the search for the optimal patient‐based frontline treatment option while evaluating a recent study by Tiribelli and colleagues, which is published in this issue of Cancer.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.34938